Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: Structure-activity relationships of novel thiohydrazone analogues

被引:93
作者
Kalinowski, Danuta S.
Sharpe, Philip C.
Bernhardt, Paul V.
Richardson, Des R. [1 ]
机构
[1] Univ Sydney, Bosch Inst, Dept Pathol, Iron Metab & Chelat Program, Sydney, NSW 2006, Australia
[2] Univ Queensland, Ctr Met Biol, Dept Chem, Brisbane, Qld 4072, Australia
关键词
D O I
10.1021/jm070839q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Di-2-pyridylketone isonicotinoyl hydrazone Fe chelators utilize the N,N,O-donor set and have moderate anti-proliferative effects. Their closely related N,N,S-thiosemicarbazone analogues, namely, the di-2pyridylketone thiosemicarbazones, exhibit markedly increased anti-proliferative and redox activity, and this was thought to be due to the inclusion of a sulfur donor atom (Richardson, D. R. et al. J. Med. Chem. 2006, 49, 6510-6521). To further examine the effect of donor atom identity on anti-proliferative activity, we synthesized thiohydrazone analogues of extensively examined aroylhydrazone chelators. The O,N,S-thiohydrazones exhibited decreased anti-proliferative effects compared to their parent aroylhydrazones and reduced redox activity. In contrast, the N,N,S-thiohydrazones showed vastly increased anti-proliferative activity compared to their hydrazone analogues, being comparable to potent thiosemicarbazones. Additionally, N,N,S-thiohydrazone complexes had reversible Fe-III/II couples and exhibited increased redox activity. These observations demonstrate that the N,N,S-donor set is critical for potent anti-proliferative efficacy.
引用
收藏
页码:6212 / 6225
页数:14
相关论文
共 79 条
[1]  
ALEKSEYEVA VV, 1981, KHIM GETEROTSIKL+, P1569
[2]  
[Anonymous], 1999, J. Appl. Crystallogr, DOI [DOI 10.1107/S0021889899006020, 10.1107/S0021889899006020]
[3]  
Armstrong CM, 2003, EUR J INORG CHEM, P1145
[4]   EVALUATION OF THE IRON CHELATION POTENTIAL OF HYDRAZONES OF PYRIDOXAL, SALICYLALDEHYDE AND 2-HYDROXY-1-NAPHTHYLALDEHYDE USING THE HEPATOCYTE IN CULTURE [J].
BAKER, E ;
RICHARDSON, D ;
GROSS, S ;
PONKA, P .
HEPATOLOGY, 1992, 15 (03) :492-501
[5]   Neurodegenerative diseases and oxidative stress [J].
Barnham, KJ ;
Masters, CL ;
Bush, AI .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) :205-214
[6]   Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs [J].
Becker, E ;
Richardson, DR .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1999, 134 (05) :510-521
[7]   Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents [J].
Becker, EM ;
Lovejoy, DB ;
Greer, JM ;
Watts, R ;
Richardson, DR .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (05) :819-830
[8]   The design, synthesis, and evaluation of organ-specific iron chelators [J].
Bergeron, Raymond J. ;
Wiegand, Jan ;
McManis, James S. ;
Bharti, Neelam .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) :7032-7043
[9]   Polyamine-vectored iron chelators: The role of charge [J].
Bergeron, RJ ;
Bharti, N ;
Wiegand, J ;
McManis, JS ;
Yao, H ;
Prokai, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (12) :4120-4137
[10]   Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues [J].
Bernhardt, PV ;
Mattsson, J ;
Richardson, DR .
INORGANIC CHEMISTRY, 2006, 45 (02) :752-760